| Objective: To explore the clinical efficacy, safety and quality of life of patients with advanced cervical cancer treated by bevacizumab combined with gemcitabine. Methods: Choose 80 patient in our hospital with advanced cervical cancer from September 2014 to September 2017, divided into two groups, 40 cases in each group, the control group treated by gemcitabine, the observation group treated by bevacizumab combined with gemcitabine. To Compared the curative effect, safety and quality of life of two groups. Results: (1)The total effective rate of the observation group was 62.5%, and the clinical control rate was 90.0%, were significantly higher than that of the control group, with total effective rate of 45.0%, and clinical control rate of 57.5% (P＜0.05). (2)Before and after treatment, the WBC, ALT of the observation group had no significant difference (t=0.76, 1.43, P＞0.05), the PLT was more significant differences (t= 5.92, P＜0.05). The PLT, ALT in the control group were more significant difference (t=4.85, 3.29, P＜0.05), there was no significant difference in the WBC of the control group before and after treatment (t=0.85, P＞0.85), the observation group ALT abnormal increased after the treatment was significantly lower than the control group (t=5.62, P＜0.05). (3)The severe adverse reaction rate of the observation group was 10.0%, significantly lower than that in the control group (?字2=12.43, P＜0.05). (4)Before treatment, there was no significant difference between the two groups in the Spitzer index (P＞0.05); after treatment, the Spitzer index in both groups was significantly higher than before treatment (P＜0.05), and the observation group was significantly higher than the control group (P＜0.05). Conclusion: The clinical curative effect of bevacizumab combined with gemcitabine treatment of advanced cervical cancer is superior to gemcitabine alone, fewer complications, higher safety, can effectively improve the quality of life, is worth promoting. |
